2.63
0.59 (28.92%)
| Penutupan Terdahulu | 2.04 |
| Buka | 2.10 |
| Jumlah Dagangan | 50,299 |
| Purata Dagangan (3B) | 70,731 |
| Modal Pasaran | 74,225,968 |
| Harga / Jualan (P/S) | 8.96 |
| Harga / Buku (P/B) | 6.27 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Nov 2022 |
| Margin Keuntungan | -60.90% |
| Margin Operasi (TTM) | -50.68% |
| EPS Cair (TTM) | -0.460 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 37.33% |
| Nisbah Semasa (MRQ) | 5.64 |
| Aliran Tunai Operasi (OCF TTM) | -9.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.06 M |
| Pulangan Atas Aset (ROA TTM) | -12.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -28.76% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | Alpha Teknova, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.50 |
|
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.95% |
| % Dimiliki oleh Institusi | 82.17% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |